Perspective Therapeutics reported third-quarter 2026 results alongside updates on three radiopharmaceutical programs targeting neuroendocrine tumors, melanoma and FAP-positive solid tumors. The company said its cash and short-term investments totaled about $202 million at quarter-end and should support its current clinical plans and operating investments into 2028.
The update also included FDA Fast Track status for PSV359, a collaboration with Merck to support possible combination testing, and progress on a manufacturing facility near Chicago. Perspective posted an updated corporate presentation on its website.
Clinical and business updates
-
Bamzireotide navoxetan (VMT-α-NET): Updated results presented at the 2026 ESMO Congress and NANETS symposium continued to support the company’s view that the treatment may have a favorable therapeutic window and potential in SSTR2-positive neuroendocrine tumors. Recruitment to dose-finding Cohort 4 closed with 20 patients enrolled. The separate meningioma cohort remained open, with two patients treated as of October 30.
-
Perspective is preparing for a potential later-stage study of bamzireotide and is targeting an end-of-Phase 2 meeting with the FDA in the first quarter of 2027. The drug received European orphan medicinal product designation in July for gastroenteropancreatic neuroendocrine tumors.
-
Lapemelanotide zapixetar (VMT01): Longer-follow-up data presented at the Society for Immunotherapy of Cancer’s annual meeting showed what the company described as durable disease control in heavily pretreated patients with MC1R-positive melanoma. Perspective is enrolling additional patients to further assess the monotherapy results.
-
As of October 30, 12 patients had received VMT01 in the monotherapy cohort, which allows up to three treatments of 3.0 mCi each, given eight weeks apart. Five patients had been treated since the cohort reopened in the third quarter. The company expects those five patients to have at least 24 weeks of follow-up by mid-2027.
-
PSV359: The dose-finding study in FAP-α-positive solid tumors advanced to its third dose cohort during the second quarter. Across the three cohorts, 17 patients had been treated by September 30. Perspective plans its next clinical update in 2027.
-
The FDA granted PSV359 Fast Track designation in October for adults with locally advanced, unresectable and/or metastatic FAP-positive solitary fibrous tumors. In September, Perspective entered a clinical trial collaboration and supply agreement with Merck to support potential evaluation of PSV359 with Keytruda in certain lung and colorectal cancers.
-
Manufacturing: Construction at the company’s Chicago-area site is expected to be completed in early 2027.
Third-quarter finances
-
Cash, cash equivalents and short-term investments were approximately $202 million on September 30, up from approximately $145 million at December 31, 2025. Perspective said the funds are expected to cover its current planned clinical milestones and operating investments into 2028.
-
Research and development expenses were $26.1 million, compared with $20.3 million in the third quarter of 2025. General and administrative expenses were $8.3 million, versus $7.7 million a year earlier.
What changes for investors
The update points to continued investment across three clinical programs, with bamzireotide moving toward FDA discussions about its next development stage. PSV359’s Fast Track status and the Merck agreement add regulatory and collaboration support, but the combination study is described as a potential evaluation rather than an announced trial result. Perspective’s stated funding outlook extends into 2028 based on its current plans.